Background
==========

Tick-borne encephalitis (TBE) is the most important viral tick-borne zoonosis in Europe \[[@B1]\]. TBE virus (TBEV) circulates between ticks and hosts in geographically strictly limited natural foci, which can range in size from large to very small. However, the reason for the patchwork-like spread of TBEV is unclear \[[@B2]-[@B4]\]. TBEV prevalence in ticks in these natural foci is very low \[[@B5]-[@B7]\], and detection of a natural TBEV focus by collecting and testing ticks is very expensive and time-consuming \[[@B8]\]. Against this background, assessment of the TBEV sero-prevalence in free-ranging animals provides a suitable and valuable additional source of information about TBEV foci in their smaller or larger patchy pattern \[[@B9]-[@B11]\].

In general, knowledge on TBE in animals is limited; however infections have been reported in dogs \[[@B12]-[@B15]\], monkeys \[[@B16],[@B17]\], and horses \[[@B4],[@B18]\]. Furthermore seroconversion without specific clinical signs of TBE has been described in some animal species such as cattle and small ruminants \[[@B11],[@B19],[@B20]\]. Clinical cases of TBE in ruminants are very seldom; one case of a mouflon (*Ovis ammon musimon*) for example has been reported from Austria \[[@B21]\]. However, these animals are of significant public health relevance. Especially goats and sheep, more rarely cattle, are of importance for the so-called alimentary TBE. During viraemia, the virus is excreted in milk and can be ingested orally by consumption of non-pasteurized milk or cheese produced from raw milk \[[@B22]-[@B25]\]. TBE in humans caused by virus-infected milk has occurred in many countries, in the last ten years in Hungary, Austria and Estonia \[[@B26]-[@B28]\].

These grazing animals have been shown to be suitable sentinels for the detection of antibodies against TBEV \[[@B11]\], but some questionable points require further examination: (i) the possibility of cross-reactivity of the tested sera with related flaviviruses and (ii) the longevity of TBEV antibody titres in grazing animals.

One example of known cross-reactivity between members of the flavivirus genus comes from serological West Nile virus (WNV) diagnostics \[[@B29]\]. WNV is considered to be the most widespread flavivirus in the world and is transmitted and maintained in an enzootic mosquito-bird cycle \[[@B30],[@B31]\]. Horses can be infected by bridge vectors and develop subclinical infection or neurological disease. False WNV positive ELISA results from horses have been attributed to cross-reactivity with TBEV specific antibodies and complicate monitoring studies on the WNV sero-prevalence \[[@B32]\].

Here we present results on cross-reactivity within the TBEV-specific serology, but also provide a strategy to identify TBEV antibodies as the cause of false positive reactions in serological tests for other flaviviruses using WNV as an example.

Methods
=======

Collection of samples
---------------------

### Sera positive for Flavivirus specific antibodies

To determine cross-reactivity, five Louping ill virus (LIV) antibody-positive reference sera from sheep (kindly provided by Kim Willoughby, Moredun-Institute, UK) as well as WNV-positive sera from the National Reference Laboratory for WNV (Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany) were tested. The WNV sample panel included 15 equine sera (field sera or sera collected after vaccination), and 10 hyperimmune-sera from vaccinated ducks, chickens and rabbits. Additionally, two rabbit sera with antibodies against Usutu virus (USUV) and Japanese encephalitis virus (JEV), respectively, were analyzed.

Furthermore, ascites liquid from mice immunized against TBEV-related viruses such as Russian-spring-summer-encephalitis virus (RSSEV), Powassan virus (POWV), Yellow fever virus (YFV), JEV and St. Louis encephalitis virus (SLEV) could be investigated (kindly provided by Gerhard Dobler, Bundeswehr Institute of Microbiology, Munich, Germany). Each sample was diluted 1:10, 1:50, 1:100, 1:500, and 1:1000 before testing (Table  [1](#T1){ref-type="table"}).

###### 

Cross-reactivities of TBEV-ELISA and TBEV-VNT results

   **Sample number**   **Animal**  **Antibodies classified as (ND**~**50**~**)**   **TBEV-ELISA**   **TBEV-VNT (ND**~**50**~**)**
  ------------------- ------------ ----------------------------------------------- ---------------- -------------------------------
        Serum 1          Sheep     Louping ill-positive                            Positive         Positive (1:20)
        Serum 2          Sheep     Louping ill-positive                            Negative         Negative (1:5)
        Serum 3          Sheep     Louping ill-positive                            Positive         Positive (\>1:40)
        Serum 4          Sheep     Louping ill-positive                            Positive         Positive (\>1:40)
        Serum 5          Sheep     Louping ill-positive                            Positive         Positive (\>1:40)
        Serum 6          Horse     WNV positive (1:320)                            Negative         Negative (\<1:10)
        Serum 7          Horse     WNV positive (1:480)                            Negative         Negative (\<1:10)
        Serum 8          Horse     WNV positive (1:1280)                           Borderline       Positive (1:40)
        Serum 9          Horse     WNV positive (1:160)                            Negative         Negative (\<1:10)
       Serum 10          Horse     WNV positive (1:240)                            Negative         Negative (\<1:10)
       Serum 11          Horse     WNV positive (1:60)                             Borderline       Positive (1:80)
       Serum 12          Horse     WNV positive (1:40)                             Negative         Negative (\<1:10)
       Serum 13          Horse     WNV positive (1:80)                             Negative         Negative (\<1:10)
       Serum 14          Horse     WNV positive (1:35)                             Negative         Negative (\<1:10)
       Serum 15          Horse     WNV positive (1:120)                            Negative         Negative (\<1:10)
       Serum 16          Horse     WNV positive (1:60)                             Negative         Negative (\<1:10)
       Serum 17          Horse     WNV positive (1:80)                             Negative         Negative (\<1:10)
       Serum 18          Horse     WNV positive (1:240)                            Negative         Negative (\<1:10)
       Serum 19          Horse     WNV positive (1:20)                             Negative         Negative (\<1:10)
       Serum 20          Horse     WNV positive (1:40)                             Negative         Negative (\<1:10)
       Serum 21          Horse     WNV positive (1:60)                             Negative         Negative (\<1:10)
       Serum 22          Horse     WNV positive (1:1280)                           Negative         Negative (\<1:10)
       Serum 23         Chicken    WNV positive (1:500)                            Negative         Negative (\<1:10)
       Serum 24         Chicken    WNV positive (1:250)                            Negative         Negative (\<1:10)
       Serum 25         Chicken    WNV positive (1:80)                             Negative         Negative (\<1:10)
       Serum 26         Chicken    WNV positive (1:900)                            Negative         Negative (\<1:10)
       Serum 27           Duck     WNV positive (1:80)                             Negative         Negative (\<1:10)
       Serum 28           Duck     WNV positive (1:60)                             Negative         Negative (\<1:10)
       Serum 29          Rabbit    WNV positive (1:120)                            Negative         Negative (\<1:10)
       Serum 30          Rabbit    WNV positive (1:480)                            Negative         Negative (\<1:10)
       Serum 31          Rabbit    WNV positive (1:80)                             Negative         Negative (\<1:10)
       Serum 32          Rabbit    WNV positive (1:60)                             Negative         Negative (\<1:10)
       Serum 33          Rabbit    JEV positive (1:60)                             Negative         Negative (\<1:10)
       Serum 34          Rabbit    JEV positive (1:80)                             Negative         Negative (\<1:10)
       Serum 35          Rabbit    USUV positive (1:1280)                          Negative         Negative (\<1:10)
       Serum 36          Rabbit    USUV positive (1:80)                            Negative         Negative (\<1:10)
       Ascites 1         Mouse     RSSEV-positive                                  Positive\*       Positive (1:75)
       Ascites 2         Mouse     POWV-positive                                   Negative\*       Negative (\<1:25)
       Ascites 3         Mouse     YFV-positive                                    Negative\*       Negative (\<1:25)
       Ascites 4         Mouse     JEV positive                                    Negative\*       Negative (\<1:25)
       Ascites 5         Mouse     SLEV positive                                   Negative\*       Negative (\<1:25)

\*all samples diluted 1:10, 1:50, 1:100, 1:500, 1:1000, only results 1:10 are shown in the table, all samples diluted between 1:50 and 1:1000 were negative.

Field sera from horses were collected in two different herds in Bavaria, and sera from TBEV-positive horses \[[@B4]\] were also included (Table  [2](#T2){ref-type="table"}).

###### 

Cross-reactivity of horse sera between ELISA and VNT

                  **TBEV-ELISA**    **TBEV-VNT**      **WNV-ELISA**      **WNV-VNT**                   
  -------------- ---------------- ---------------- -------------------- ------------- ---------------- -------------
      Sample          U/l 1            Result           ND~**50**~          S/N%           Result       ND~**50**~
     Serum 1          -2,995          Negative             n.d.            92,25%         Negative        \< 1:10
   **Serum 2**      **12,500**     **Borderline**   **\>1:640/1:960**    **11,99%**     **Positive**    **\< 1:10**
     Serum 3          -2,938          Negative             n.d.            88,04%         Negative        \< 1:10
     Serum 4          -3,802          Negative             n.d.            94,11%         Negative        \< 1:10
     Serum 5          3,859           Negative             n.d.            41,48%        Borderline       \< 1:10
   **Serum 6**      **17,627**      **Positive**         **1:80**         **7,27%**     **Positive**    **\< 1:10**
     Serum 7          -2,650          Negative             n.d.            77,31%         Negative        \< 1:10
     Serum 8          -3,571          Negative             n.d.            86,93%         Negative        \< 1:10
     Serum 9          -3,168          Negative             n.d.            90,48%         Negative        \< 1:10
     Serum 10         3,111           Negative             n.d.             3,16%         Negative        \< 1:10
     Serum 11         -0,806          Negative             n.d.            93,43%         Negative        \< 1:10
     Serum 12         -3,975          Negative             n.d.            93,54%         Negative        \< 1:10
     Serum 13         -2,995          Negative             n.d.            92,59%         Negative        \< 1:10
     Serum 14         -3,744          Negative             n.d.            89,52%         Negative        \< 1:10
     Serum 15         -2,995          Negative             n.d.            88,38%         Negative        \< 1:10
     Serum 16         4,896           Negative             n.d.            86,58%         Negative        \< 1:10
     Serum 17         -3,168          Negative             n.d.            85,80%         Negative        \< 1:10
     Serum 18         -2,765          Negative             n.d.            91,29%         Negative        \< 1:10
   **Serum 19**     **17,915**      **Positive**         **1:80**        **15,04%**     **Positive**    **\< 1:10**
     Serum 20         20,392          Positive            1:240            51,14%         Negative        \< 1:10
   **Serum 21**     **12,212**     **Borderline**       **1:160**        **13,51%**     **Positive**    **\< 1:10**
   **Serum 22**     **17,569**      **Positive**        **1:320**         **9,48%**     **Positive**    **\< 1:10**
     Serum 23         -3,053          Negative             n.d.            84,21%         Negative        \< 1:10
     Serum 24         -3,399          Negative             n.d.            83,57%         Negative        \< 1:10
   **Serum 25**     **16,993**      **Positive**         **1:80**         **7,06%**     **Positive**    **\< 1:10**
     Serum 26         -4,818          Negative             n.d.            89,77%         Negative        \< 1:10
     Serum 27         -5,867          Negative             n.d.            83,66%         Negative        \< 1:10
     Serum 28         -3,959          Negative             n.d.            84,43%         Negative        \< 1:10
     Serum 29         -5,295          Negative             n.d.            91,08%         Negative        \< 1:10
     Serum 30         10,351         Borderline           \<1:5            86,85%         Negative        \< 1:10
     Serum 31         -5,200          Negative             n.d.            86,23%         Negative        \< 1:10
     Serum 32         -4,532          Negative             n.d.            86,37%         Negative        \< 1:10
   **Serum 33**     **31,245**      **Positive**     **\>1:40/1:720**    **27,45%**     **Positive**    **\< 1:10**
     Serum 34         14,168          Positive         \>1:40/1:480        76,10%         Negative        \< 1:10
   **Serum 35**     **21,991**      **Positive**         **1:40**        **40,69%**    **Borderline**   **\< 1:10**
   **Serum 36**     **35,443**      **Positive**    **\>1:40/\>1:960**   **21,43%**     **Positive**    **\< 1:10**
     Serum 37         -5,581          Negative             n.d.            86,84%         Negative        \< 1:10
     Serum 38         -4,913          Negative            \<1:5            88,36%         Negative        \< 1:10
   **Serum 39**     **35,538**      **Positive**     **\>1:40/1:480**     **6,68%**     **Positive**    **\< 1:10**
   **Serum 40**     **30,291**      **Positive**     **\>1:40/1:960**    **17,62%**     **Positive**    **\< 1:10**
     Serum 41         -5,200          Negative            \<1:5            85,33%         Negative        \< 1:10
     Serum 42         -3,864          Negative             n.d.            86,76%         Negative        \< 1:10
     Serum 43         -5,486          Negative             n.d.            87,18%         Negative        \< 1:10
     Serum 44         -3,959          Negative             n.d.            87,91%         Negative        \< 1:10
     Serum 45         -5,200          Negative             n.d.            86,37%         Negative        \< 1:10
   **Serum 46**     **13,691**      **Positive**    **\>1:40/\>1:960**    **3,07%**     **Positive**    **\< 1:10**

In bold = TBEV-positive horses would result in false positive outcomes in the commercial WNV-ELISA, but clearly negative in the WNV-specific VNT.

n.d. = not done.

### Sera collected to analyze the longevity of the humoral immune response

Two goats and two sheep were immunized four times as described by Klaus et al. \[[@B33]\] and TBEV antibody titres were traced over a period of 28 months (Table  [3](#T3){ref-type="table"}).

###### 

Longevity of TBEV-antibody titres (VNT) in two immunized goats and sheep

   **Month\***   **Goat 1\*\***   **Goat 2\*\***   **Sheep 1\*\***   **Sheep 2\*\***
  ------------- ---------------- ---------------- ----------------- -----------------
        0            \<1:5            \<1:5             \<1:5             \<1:5
        6             1:60             1:80             1:80              1:80
       12             1:80            1:120             1:80              1:80
       18             1:60            1:320             1:10              1:20
       24             1:30            1:120             1:30              1:20
       28             1:80             1:80             1:30              1:60

\*sera examined every month, only selected data shown.

\*\*immunized in week 0, 1, 3 and 11 with one dose of FSME-IMMUN Erwachsene (Baxter Deutschland GmbH, Germany), as described in \[[@B33]\].

\<1:5 = negative.

In addition, different field sera were included in the analysis: sera from sheep and goat flocks from the TBE risk areas "Ortenaukreis", "Bodenseekreis" and "Breisgau-Hochschwarzwald (HS)", and sera from the TBE non-risk area "Altenburger Land" which were collected in 2010 and 2011 (Table  [4](#T4){ref-type="table"}). Although the sera did not come from the same individual animals, the datasets were compared to the sero-prevalence results exhibited by the same flocks in 2006 and 2009 \[[@B11]\].

###### 

Re-tested goat flocks for TBEV-specific antibodies (Thuringia-TH, Baden-Wuerttemberg-BW) and sheep flocks (Baden-Wuerttemberg-BW), re-collected in 2010/11

  **Country**   **District**       **Flock (village)**     **Year**    **Species**   **No. of sera**   **No. of positive sera**   **Seroprev. (%)**
  ------------- ------------------ ---------------------- ----------- ------------- ----------------- -------------------------- -------------------
  BW            Bodenseekreis      S1 (Salem)                2011         sheep            100                    13                     13
  BW            Bodenseekreis      S1 (Salem)              2008-09\*      sheep            100                    9                       9
  BW            Breisgau (HS)      Sulzburg                  2010         goats            28                     5                     17,8
  BW            Breisgau (HS)      Sulzburg                2006-09\*      goats            28                     12                     43
  BW            Breisgau (HS)      different flocks\*\*      2010         goats            355                    4                      1,1
  BW            Breisgau (HS)      different flocks\*\*    2006-09\*      goats            349                    13                     3,7
  BW            Ortenaukreis       Nordrach                  2010         goats            28                     12                    42,8
  BW            Ortenaukreis       Nordrach                 2008\*        goats            20                     12                     60
  BW            Ortenaukreis       various flocks\*\*\*      2010         goats            100                    15                     15
  BW            Ortenaukreis       various flocks           2008\*        goats            355                    51                    14,4
  TH            Altenburger Land   A1 (Altkirchen)           2011         goats            90                     0                       0
  TH            Altenburger Land   A1 (Altkirchen)          2009\*        goats            73                     5                       7

\*in detail published in \[[@B11]\].

\*\*re-tested flocks from Horben, Münstertal and Löffingen-Dittishausen, results not shown in detail.

\*\*\*flocks from Haslach, Kürzell-Meißenheim, Offenburg, Hohberg, results not shown in detail.

In addition, in Salem, district Bodenseekreis, not only sera but also ticks were collected in 2011 (89 female, 116 male, 1537 nymphs, 46 larvae) in the vicinity of the monkey mountain, where in 2006 TBEV strain Salem had first been isolated from a monkey (*Macaca sylvanus*) \[[@B16],[@B17]\] and sheep sera had been collected and examined in 2008/2009 \[[@B34]\], but TBEV-RNA in ticks has not been detected so far. Ticks were pooled (up to 5 female, 5 male, 10 nymphs, 20 larvae), examined for TBEV-RNA and positive pools were sequenced as described \[[@B4]\].

Test systems
------------

### TBEV specific serology

All sera were examined by means of a two-step method \[[@B33],[@B34]\], which consisted of (I) first screening with a modified TBEV-antibody ELISA (Immunozym FSME IgM kit, Progen GmbH, Heidelberg, Germany) allowing analysis of the whole immunoglobulin fraction and (II) subsequent confirmation of all ELISA-positive or questionable results by a virus neutralization test (VNT; \[[@B10]\]). Only sera confirmed by VNT were finally classified as TBEV antibody positive.

### WNV specific serology

For detection of WNV-specific antibodies, horse samples were investigated by a commercially available competition ELISA, which allows the species-independent recognition of WNV antibodies against the PrM- and E envelope protein (ID Screen® West Nile Competition, IDVet, Grabels, France). Additionally, all serum samples were tested for neutralizing WNV antibodies by VNT with the WNV strain NY 99 (lineage 1, accession no. AF196835) and/or strain Austria (lineage 2, accession no. HM015884, kindly provided by Dr. N. Nowotny, Institute of Virology, University of Veterinary Medicine, Vienna) as described previously \[[@B35]\].

Results
=======

Cross-reactivity in TBEV-serology
---------------------------------

The majority of samples from the tested Flavivirus-antibody-positive-panel (Table  [1](#T1){ref-type="table"}) showed clearly negative results using the TBEV-ELISA. Sera with specific antibodies to non-TBEV flaviviruses*,* such as WNV, JEV, USUV, YFV, SLEV or POWV, scored also clearly negative using the TBEV-ELISA. Nevertheless, four out of five LIV-antibody-positive sheep sera reacted positive in the TBEV-ELISA as well as in the TBEV-VNT. In addition, RSSEV reactive mouse ascites scored also positive in both, the TBEV-ELISA and the TBEV-VNT, but only at the lowest dilution of 1:10 (Table  [1](#T1){ref-type="table"}).

Cross-reactivity in WNV serology
--------------------------------

The fifteen WNV-positive horse sera were classified as clearly negative in the TBEV-ELISA, which was confirmed by the TBEV-VNT. Furthermore, 10 WNV-specific hyperimmune sera from vaccinated chickens, ducks and rabbits were clearly negative both in the TBEV-ELISA and the TBEV-VNT. The same could be shown for the two hyperimmune sera from JEV and USUV vaccinated rabbits, respectively (Table  [1](#T1){ref-type="table"}). Therefore, WNV-specific antibodies did not obviously cross- react with our TBEV-specific serology testing.

In contrast, WNV-negative (verified by WNV-specific VNT) horse sera scored positive in the commercial WNV-ELISA. Here it could be verified that TBEV-specific antibodies (ELISA and VNT) were the source of cross-reactivity. These results therefore indicate that TBEV-specific antibodies did interfere with WNV-specific ELISA diagnostics and have to be taken into account (Table  [2](#T2){ref-type="table"}).

Longevity of TBEV-specific antibody titres in immunized animals and re-testing of sentinel flocks for long-term observations
----------------------------------------------------------------------------------------------------------------------------

The development of TBEV-specific antibody titres over a time span of more than two years is shown in Table  [3](#T3){ref-type="table"}. TBEV-specific antibody titres increased in the vaccinated sheep and goats until 18 weeks after the first immunization and started to decrease to lower VNT titres over the following weeks to reach lower but still positive titres 28 months after vaccination (Table  [3](#T3){ref-type="table"}).

In order to track the development of TBEV-antibodies in the field situation, selected flocks in Baden-Wuerttemberg and Thuringia (Table  [4](#T4){ref-type="table"}) were repeatedly tested within a time interval of one to four years. Interestingly, the initial results reported for the districts "Bodenseekreis", "Breisgau-HS", and "Ortenaukreis" (Baden-Wuerttemberg), were confirmed \[[@B11]\]. For example, in the sheep flock in Salem (district "Bodenseekreis") a TBEV-sero-prevalence of 13% was detected (in 2008/2009: 9%), in the goat flock in "Sulzburg" (district "Breisgau-HS") 17.8% were seen (2006--09: 43%), and in a goat flock in "Nordrach" (district "Ortenaukreis") 42.8% scored positive (2008: 60%). These findings are in good agreement with the TBE-risk-area status as determined by the Robert Koch-Institute \[[@B36],[@B37]\].

All animal experiments in this study were conducted in strict accordance with a high standard of veterinary care. The protocols were approved by the competent authority of the Federal State of Thuringia, Thuringian State Office for Food Safety and Consumer Protection, Dept. of Health Protection, Veterinary Medicine and Pharmacy, Bad Langensalza, Thuringia, Germany (Reg. no. 04-104/10) and reviewed and approved by the competent authority of the Federal State of Mecklenburg-Western Pomerania, State Office for Agriculture, Food Safety and Fisheries, Rostock, Mecklenburg-Western Pomerania, Germany (LALLF M-V/TSD/7221.3-2.5.1-002/11).

In addition to these serological results in Salem (Bodenseekreis) 1788 collected ticks in 208 pools were analyzed by TBEV-specific RT-qPCR and in one pool of 10 nymphs collected around the monkey mountain TBEV-RNA was detected. The nucleotide sequence (2866 nt in total) of the structure protein genes of TBEV were determined (GenBank KC292217) and compared with the TBEV sequences available in the NCBI GenBank database using BLAST. The highest homology with 99.55% was ascertained for TBEV strain Salem (GenBank FJ572210). Here 2853 nt of the compared 2866 nt were identical.

Interestingly, the results from a flock in Thuringia surveyed in 2009 could not be confirmed: In 2009, surprisingly five out of 73 sera in this goat flock in "Altkirchen" in the district "Altenburger Land", Thuringia, which is defined as a TBE non-risk area, tested TBEV-antibody-positive \[[@B11]\]. In 2011, we tested 90 sera from this flock and did not find any TBEV-antibody-positive sera (Table  [4](#T4){ref-type="table"}). The map (Figure  [1](#F1){ref-type="fig"}) shows the four districts where sera were collected.

![**Places of re-tested flocks in Baden-Wuerttemberg and Thuringia.** 1: Bodenseekreis; 2: Breisgau-Hochschwarzwald; 3: Ortenaukreis; 4: Altenburger Land; star: in addition tick collection site.](1746-6148-10-78-1){#F1}

Discussion
==========

A limited cross-reactivity of non-TBEV, but flavivirus-antibody-positive sera was observed in the TBEV-specific test strategy (ELISA and VNT) used for the selection of regions with a risk for TBEV infection. Four of five sera defined as LIV-antibody positive and ascites from a RSSEV-infected mouse reacted positive in the ELISA as well as in the VNT assay (Table  [1](#T1){ref-type="table"}). Therefore, TBEV-serology in most cases is not able to differentiate between LIV-antibody-positive, RSSEV-antibody-positive and TBEV-antibody-positive sera, and an intense cross-reactivity of sera specific for these related viruses must be assumed. Phylogenetic analysis of the genus Flavivirus confirmed the close relationship of LIV, RSSEV and TBEV \[[@B38]\]. However, since to our knowledge human TBE cases have not been described in Great Britain \[[@B1],[@B39]\], it must be concluded that double infection with Louping ill and TBEV as a reason for these results can be excluded. Cross-reactivity would only be relevant in countries where both diseases are present. In Germany, Louping ill as well as RSSE has not been observed to date \[[@B39]\]. In addition, clinical signs of Louping ill in sheep are severe, while TBE infection in ruminants normally is subclinical \[[@B39]-[@B41]\].

Furthermore, no cross-reactivity was observed between our TBEV test system (ELISA and VNT) and defined WNV-positive horse sera (Table  [1](#T1){ref-type="table"}).

It is well-known, that the used commercial competitive WNV-ELISA cross-reacts with other flaviviruses \[[@B29],[@B32]\], necessitating the use of virus-specific neutralization assays for the final determination of the etiologic flavivirus. Here, the cumulative occurrence of false-positive WNV-results with the used commercial WNV-ELISA system (Table  [2](#T2){ref-type="table"}) is the consequence of a clear cross-reactivity with TBEV-specific antibodies. In this case, a reasonable discrimination is only possible by means of a virus-specific neutralization assay. The results of this study are therefore in good agreement with those of a previous study \[[@B29]\]. In Germany, TBEV-related diseases in horses have been reported recently \[[@B4],[@B42]\]. Müller et al. \[[@B42]\] investigated a population of 240 horses in the endemic region of Marburg-Biedenkopf and identified 2.9% horses with TBEV-neutralizing antibodies. Consequently, TBEV should be considered as an important and relevant differential diagnosis for WNV infections in horses, although there is no evidence for indigenous WNV infections in Germany so far \[[@B32]\]. Our results are in accordance with a similar study in Austria, where an unexpectedly high seroconversion rate against TBEV was identified in a large herd of horses \[[@B43]\]. Therefore, our TBEV test system could also be helpful for clarifying non-specific serological WNV antibody-reactive results in regions without a WNV history.

On the other hand, testing of horses can even be used as an indicator to detect TBEV-affected areas and thus identify a TBEV focus.

In summary, our TBEV antibody test system is well suited and, despite a partial cross-reactivity to LIV- and RSSEV-antibodies, cross-reactivity with other flaviviruses is not to be expected in countries like Germany. However, the number of samples tested so far has been low, so these findings should be verified in future studies.

In our investigations on the longevity of TBEV antibody titres, only small differences were seen between the two immunized goats and sheep. TBEV-specific antibody titres were still detectable after 28 months with lower but specific titres in the two goats and two sheep (Table  [3](#T3){ref-type="table"}). While the progress of TBEV antibody titres reflects the situation after immunization with an inactivated vaccine, natural infection might result in relatively similar humoral immune responses; e.g. in horses it was possible to re-test naturally infected TBEV-antibody-positive animals. In two flocks in Bavaria, all six TBEV antibody-positive horses which were re-tested after nine months had VNT-positive titres and it was also possible to detect TBEV in ticks collected in the vicinity of the stables \[[@B4]\]. Also Leschnik et al. \[[@B14]\] observed TBEV titres in dog sera for nine months after natural infection.

In addition, in repeatedly tested goat and sheep flocks the detected sero-prevalences were in good accordance with the epidemiological TBEV situation in the surroundings. In the district "Bodenseekreis", a defined TBE risk area with a very long TBEV history, 60 human cases were registered between 2001 and 2012, and the existence of a TBEV natural focus in Salem described in animals in 2006 \[[@B16],[@B17],[@B34]\] was re-confirmed by TBEV antibody-positive sheep sera (Table  [4](#T4){ref-type="table"}). Detection of TBEV-RNA (GenBank KC292217) closely related to the TBEV strain "Salem"(GenBank FJ572210) in one pool of 10 nymphs among 1788 collected ticks also confirmed the serological results (data not shown in detail). This strain was first isolated and sequenced from a monkey (*Macaca sylvanus*) from the monkey mountain Salem with severe neurological clinical symptoms in 2006 \[[@B16],[@B17]\]. However, until our here presented results TBEV-RNA could not be found in ticks at this place. . After our investigations in horse herds in Bavaria \[[@B4]\] it was an additional case where sera from grazing animals as sentinels were successfully used for a targeted tick collection to detect TBEV-RNA.

The districts "Breisgau-HS" and "Ortenaukreis" also have a well-known TBEV history with 64 (Breisgau-HS) and 246 (Ortenaukreis) human cases, respectively, between 2001 and 2012.

In the goat flock in "Altkirchen", district "Altenburger Land" (Thuringia), however, re-testing provided a different unexpected result. Surprisingly, in 2009, five of 73 sera from this TBE non-risk area with so far no human TBE cases had been found to be TBEV antibody-positive (7%). In 2011, 90 sera from new goats of this flock were re-tested and no TBEV antibody-positive results were detected (Table  [4](#T4){ref-type="table"}). One reasonable explanation might be the elimination of the relevant animals from the flock, since persistence of TBEV-specific antibody titres is possible for more than 28 months.

Therefore, detection of a small number of TBEV antibody-positive sera in TBEV non-risk areas with no human TBE cases should be interpreted with care (animals might originate from TBE risk areas). However, the longevity data support the conclusion that sera from grazing animals are well suited as a valuable source of serological data supporting the TBEV status of an area.

Conclusions
===========

TBEV-specific sero-prevalences in animals are an additional valuable tool that can help identify natural TBEV foci which are in most cases spread in a patchwork-like pattern. Cross-reactivity is rare and does not play a significant role in countries without a prevalence of a broad range of TBEV-related flaviviruses. Furthermore, TBEV is a very important and relevant cause for false-positive WNV-ELISA results in horses and must be taken into consideration in monitoring or sentinel programs.

Finally, all TBEV serology results should be interpreted in close cooperation between human and veterinary medicine, and recommendations for the vaccination of humans, based exclusively on the TBEV sero-prevalence in animals should be avoided.
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